We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0W8U market cap is 7,052.68T. The company's latest EPS is EUR -0.0146 and P/E is -1989041095.89.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 114k | 171k | 30k | 34k | 12k |
| Operating Income | -13.08M | -8.18M | -3.49M | -7.83M | -6.44M |
| Net Income | -10.78M | -7.55M | -6.14M | -11.84M | -3.55M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 7.24M | 7.63M | 13.53M | 48.55M | 55.29M |
| Total Liabilities | 4.8M | 5.87M | 3.51M | 4.65M | 5.13M |
| Total Equity | 2.44M | 1.76M | 10.02M | 43.9M | 50.17M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -13.31M | -8.1M | -5.65M | -9.91M | -4.45M |
| Investing | -31k | 42k | -221k | -18.81M | -31.56M |
| Financing | 9.61M | 7.94M | 14.65M | 51.75M | 9.99M |
| Market Cap | 7,052.68T |
| Price to Earnings Ratio | -1989041095.89 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 145.2B |
| Price to Book Ratio | 140.59M |
| Dividend Yield | - |
| Shares Outstanding | 242.86M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 29,040,000.00 |
| 52 Week Low | 29,040,000.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Neovacs Sa |
| Address |
3-5 impasse reille paris, paris 75014 |
| Website | https://www.neovacs.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
